Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. (SHE:300937)
China · Delayed Price · Currency is CNY 24.58
-0.78 (-3.08%)
At close: Jul 16, 2026
SHE:300937 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 4,397 | 4,421 | 4,360 | 4,407 | 3,946 | 3,384 |
Other Revenue | 33.06 | 33.06 | 34.68 | 23.54 | 23.65 | 16.23 |
| 4,430 | 4,454 | 4,395 | 4,430 | 3,969 | 3,401 | |
Revenue Growth (YoY) | 3.16% | 1.35% | -0.81% | 11.62% | 16.72% | 21.88% |
Cost of Revenue | 3,983 | 3,995 | 4,012 | 4,073 | 3,663 | 3,219 |
Gross Profit | 446.87 | 459.48 | 382.22 | 357.85 | 306.05 | 181.48 |
Selling, General & Admin | 393.02 | 401.55 | 327.84 | 247.44 | 218.86 | 164.5 |
Research & Development | 10.47 | 10.72 | 15.47 | 19.32 | 17.71 | 11.38 |
Other Operating Expenses | 8.79 | 9.02 | 7.28 | 7.4 | 6.47 | 5.11 |
Operating Expenses | 423.9 | 431.54 | 356.81 | 283.89 | 247.86 | 181.44 |
Operating Income | 22.98 | 27.94 | 25.41 | 73.97 | 58.19 | 0.04 |
Interest Expense | -8.49 | -9.09 | -9.71 | -6.58 | -6.42 | -1.82 |
Interest & Investment Income | 2.63 | 2.98 | 3.88 | 3.81 | 2.38 | 9.65 |
Currency Exchange Gain (Loss) | -0 | -0 | 0 | -0 | -0 | - |
Other Non Operating Income (Expenses) | -8.49 | -8.88 | -4.89 | -6.17 | -10.31 | -3.94 |
EBT Excluding Unusual Items | 8.63 | 12.95 | 14.69 | 65.02 | 43.83 | 3.93 |
Impairment of Goodwill | -5 | -5 | -3.24 | - | -1.62 | - |
Gain (Loss) on Sale of Investments | -0.36 | -0.36 | -1.11 | - | -4.29 | - |
Gain (Loss) on Sale of Assets | -0.01 | -0.01 | -0.61 | -0.05 | -0.08 | -0.11 |
Asset Writedown | 0.37 | -0.89 | 0.4 | -0.01 | -0.11 | -0 |
Other Unusual Items | 0.49 | 0.49 | 1.83 | 4.92 | 7.16 | 4.3 |
Pretax Income | 4.11 | 7.18 | 11.96 | 69.88 | 44.89 | 8.12 |
Income Tax Expense | 23.63 | 23.63 | 0.96 | 13.11 | 8.75 | 1.4 |
Earnings From Continuing Operations | -19.52 | -16.46 | 11 | 56.77 | 36.14 | 6.73 |
Minority Interest in Earnings | -0.24 | 3.6 | 2.2 | 2.76 | 5.88 | -0.33 |
Net Income | -19.76 | -12.85 | 13.2 | 59.53 | 42.02 | 6.4 |
Net Income to Common | -19.76 | -12.85 | 13.2 | 59.53 | 42.02 | 6.4 |
Net Income Growth | - | - | -77.83% | 41.69% | 556.48% | -88.15% |
Shares Outstanding (Basic) | 93 | 96 | 78 | 96 | 95 | 91 |
Shares Outstanding (Diluted) | 93 | 96 | 78 | 96 | 95 | 91 |
Shares Change (YoY) | 19.52% | 23.24% | -19.13% | 0.56% | 4.44% | 26.94% |
EPS (Basic) | -0.21 | -0.13 | 0.17 | 0.62 | 0.44 | 0.07 |
EPS (Diluted) | -0.21 | -0.13 | 0.17 | 0.62 | 0.44 | 0.07 |
EPS Growth | - | - | -72.58% | 40.91% | 528.57% | -90.67% |
Free Cash Flow | 19.2 | -20.8 | 92.02 | -150.8 | 134.35 | -185.81 |
Free Cash Flow Per Share | 0.21 | -0.22 | 1.19 | -1.57 | 1.41 | -2.03 |
Dividend Per Share | - | - | 0.100 | 0.220 | 0.200 | - |
Dividend Growth | - | - | -54.55% | 10.00% | - | - |
Gross Margin | 10.09% | 10.32% | 8.70% | 8.08% | 7.71% | 5.34% |
Operating Margin | 0.52% | 0.63% | 0.58% | 1.67% | 1.47% | 0.00% |
Profit Margin | -0.45% | -0.29% | 0.30% | 1.34% | 1.06% | 0.19% |
Free Cash Flow Margin | 0.43% | -0.47% | 2.09% | -3.40% | 3.38% | -5.46% |
EBITDA | 42.9 | 48.07 | 46.37 | 93.03 | 77.46 | 13.37 |
EBITDA Margin | 0.97% | 1.08% | 1.05% | 2.10% | 1.95% | 0.39% |
D&A For EBITDA | 19.92 | 20.13 | 20.96 | 19.06 | 19.27 | 13.33 |
EBIT | 22.98 | 27.94 | 25.41 | 73.97 | 58.19 | 0.04 |
EBIT Margin | 0.52% | 0.63% | 0.58% | 1.67% | 1.47% | 0.00% |
Effective Tax Rate | 574.32% | 329.27% | 8.06% | 18.76% | 19.50% | 17.17% |
Revenue as Reported | 4,430 | 4,454 | 4,395 | - | 3,969 | 3,401 |
Advertising Expenses | - | 136.34 | 76.51 | 36.27 | 28.48 | 19.98 |